Singapore, Nov. 10 -- The Emirates Drug Establishment (EDE) has granted conditional approval for a new indication of AstraZeneca's Ultomiris(R) (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression, making the UAE the first country in the world to approve this indication. Ultomiris(R) has been registered in the UAE since 2022 for the treatment of several rare diseases.

The approval is in line with the UAE's strategic priorities and the "We the UAE 2031" vision, which aims to strengthen the country's leadership and global competitiveness in vital sectors, particularly healthcare and pharmaceuticals, while advancing innovation, research and development.

It als...